CCL2 and chronic kidney disease: Recently, it has been shown that a six months treatment with curcumin formulated in phytosomes (Meriva®, Indena SpA, Milan, Italy, 500 mg tablet × 2/day, equivalent of 100 mg curcuminoids/tablet) significantly reduced plasma pro-inflammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1/CCL-2), IFNγ and IL-4, as well as lipid peroxidation products (thiobarbituric acid reactive substances, TBARS) in chronic kidney disease patients [140].